Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial - Day, J W; Finkel, R S; Chiriboga, C A; Connolly, A M; Crawford, T O; Darras, B T (The Lancet Neurology, 2021)
et al.